HRMY
Harmony Biosciences Holdings, Inc.- Healthcare
- Biotechnology
- $2.40B market cap
Forecast run · Sep 14, 2026Upside rank 1311 of 3,136
Model Signal
ForecastQ Daily Probabilities
39.0%
35.3%
14.1%
Analyst Consensus
Recommendation2.54/5 Hold
Last price$41.52
Price target$48.50
Implied move+16.8%
Analysts13
ForecastQ Portfolios
HRMY is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.
Company Profile
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.